Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | DRD3 | P35462 | 2/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1897774 | 0.99 | TAS2R14 (0.34) | TAS2R14CETPCXCR3PTGDR2DRD2 | |
| SCHEMBL3539947 | 0.99 | CETP (0.34) | TAS2R14CETPCXCR3PTGDR2DRD2 | |
| Hydrochloric Acid SCHEMBL1903284 | 0.98 | CETP (0.33) | TAS2R14CETPCXCR3PTGDR2DRD2 | |
| SCHEMBL4830767 | 0.93 | CETP (0.38) | TAS2R14CETPCXCR3PTGDR2MMP13 | |
| SCHEMBL1899995 | 0.93 | CETP (0.34) | CETPDRD2DRD3 | |
| Bicarbonate SCHEMBL5197147 | 0.93 | CETP (0.33) | CETPCXCR3 | |
| Hydrochloric Acid SCHEMBL1903810 | 0.93 | CETP (0.37) | TAS2R14CETPCXCR3PTGDR2MMP13 | |
| Hydrochloric Acid SCHEMBL1900943 | 0.92 | CETP (0.34) | CETPDRD2DRD3 | |
| SCHEMBL4830761 | 0.92 | CETP (0.38) | TAS2R14CETPCXCR3PTGDR2 | |
| SCHEMBL1902292 | 0.92 | CETP (0.34) | CETPDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | claimed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | claimed |
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | TAS2R14 3220/4885CETP 1/4885CXCR3 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.